194 related articles for article (PubMed ID: 35098335)
1. Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia.
Li L; Xiao Z; Wang Y; He Y; Wang Z; Shen D; Wang J
Arch Gynecol Obstet; 2023 Jun; 307(6):2025-2031. PubMed ID: 35098335
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer].
Morimoto C; Wang YQ; Zhou R; Wang JL
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):936-942. PubMed ID: 36241236
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
4. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
[No Abstract] [Full Text] [Related]
5. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].
Wang YQ; Kang N; Li LW; Wang ZQ; Zhou R; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):692-700. PubMed ID: 36177581
[No Abstract] [Full Text] [Related]
6. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
7. [Analyze of obesity indicators and effect of fertility preservation treatment in patients with endometrial atypical hyperplasia and early endometrial cancer].
Bo LL; Wang YQ; Liu YY; Li XD; Zhou R; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2022 Oct; 57(10):767-774. PubMed ID: 36299180
[No Abstract] [Full Text] [Related]
8. [Clinical outcomes analysis of fertility-preserving therapy for atypical endometrial hyperplasia and early endometrial carcinoma].
He YJ; Wang YQ; Dai YB; Zhou R; Lu Q; Liu GL; Wang JL
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):291-296. PubMed ID: 35316880
[No Abstract] [Full Text] [Related]
9. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
10. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
11. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
[TBL] [Abstract][Full Text] [Related]
13. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
[No Abstract] [Full Text] [Related]
15. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and prognosis of fertility-preserved hysteroscopic surgery combined with progesterone in the treatment of complex endometrial hyperplasia and early endometrial carcinoma.
Xu Z; Tian Y; Fu J; Xu J; Bao D; Wang G
J BUON; 2020; 25(3):1525-1533. PubMed ID: 32862600
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
[TBL] [Abstract][Full Text] [Related]
18. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
19. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
20. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.
Vaugon M; Peigné M; Phelippeau J; Gonthier C; Koskas M
Reprod Biomed Online; 2021 Sep; 43(3):495-502. PubMed ID: 34315696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
